New report issued by Global AMR R&D Hub and WHO
Increasing cases of antibiotic resistance endanger global health and the availability of modern healthcare. Till date, the situation for the antibiotics supply chain is that there is a general lack for existing generic products, and too little new and innovative products coming to market.
Without sufficient action, we are unavoidably doomed to re-enter an era where routine operations pose a threat to our lives. The problem being that bringing a new antibiotic to market is a resource intensive undertaking with a relatively low return on investment, many big pharmaceutical companies have shut down activities on antibiotic development. Those companies remaining active struggle to sustain their operations. Not surprisingly, therefore, since 1987, no new ground-breaking antibacterial treatments have reached the market for Gram-negative bacteria. As stated in the World Health Organization’s most recent report “2021 antibacterial agents in clinical and preclinical development: an overview and analysis”, only 79 new antibacterial treatments are in development. Of these, most are derivates of already existing antibiotic classes, and the majority are unlikely to reach the market.
The Global AMR R&D Hub’s studies evaluating the magnitude of the issue of successfully bringing new antibiotics onto the market under the current economic conditions underline the mismatch between global patient needs and the commercial potential of products. The immediate adaptation of national health systems tools combined with pull incentives was called for to both support innovation and provide access to the products to those who need them the most.
Read the full report here: https://globalamrhub.org/wp-content/uploads/2022/05/G7_ProgressReport_FINAL_16.05.2022.pdf